lisade Bio announced the completion of all five planned Single Ascending Dose, SAD, cohorts and the commencement of the Multiple Ascending Dose cohorts in its ongoing Phase 1a/b study of PALI-2108 for the treatment of Ulcerative Colitis, UC. Preliminary data from the SAD portion of the study, which evaluated doses ranging from 15 mg to 450 mg of PALI-2108, support that the drug was well-tolerated across all dose levels. Importantly, there were no treatment-related dose reductions, serious adverse events, SAEs, or treatment-related laboratory abnormalities observed. Treatment-emergent adverse events , TEASs, were mild and occurred only at the highest dose of 450 mg. Importantly, there were no EKG abnormalities or other serious safety concerns, underscoring the favorable safety profile of PALI-2108.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PALI: